Home Cart Sign in  
Chemical Structure| 147539-41-1 Chemical Structure| 147539-41-1

Structure of 147539-41-1

Chemical Structure| 147539-41-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of [ 147539-41-1 ]

CAS No. :147539-41-1
Formula : C11H22N2O2
M.W : 214.30
SMILES Code : O=C(N1CCC(NC)CC1)OC(C)(C)C
MDL No. :MFCD02259411
InChI Key :CZYUGTLMFHDODF-UHFFFAOYSA-N
Pubchem ID :15380702

Safety of [ 147539-41-1 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H317-H319
Precautionary Statements:P280-P305+P351+P338

Computational Chemistry of [ 147539-41-1 ] Show Less

Physicochemical Properties

Num. heavy atoms 15
Num. arom. heavy atoms 0
Fraction Csp3 0.91
Num. rotatable bonds 4
Num. H-bond acceptors 3.0
Num. H-bond donors 1.0
Molar Refractivity 64.2
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

41.57 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

2.87
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

1.24
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

1.22
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

1.15
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

0.76
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

1.45

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-1.69
Solubility 4.42 mg/ml ; 0.0206 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-1.71
Solubility 4.17 mg/ml ; 0.0195 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Very soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-1.72
Solubility 4.08 mg/ml ; 0.0191 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

No
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-6.73 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

0.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

2.24

Application In Synthesis of [ 147539-41-1 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 147539-41-1 ]

[ 147539-41-1 ] Synthesis Path-Downstream   1~5

  • 1
  • [ 263400-88-0 ]
  • [ 147539-41-1 ]
  • 4-[(3-methanesulfonyl-propyl)-methyl-amino]-piperidine-1-carboxylic acid tert-butyl ester [ No CAS ]
YieldReaction ConditionsOperation in experiment
With potassium acetate; In acetonitrile;Heating / reflux; 152 (l-r2-(lH-Indazol-4-ylV4-morpholin-4-yl-thienor3.2-d1pyrimidin-6-ylmethyl1- piperidin-4-vU-(3-methanesulfonyl-propylVmethyl-amine.Via [ 1 -(2-chloro-4-morpholin-4-yl-thieno[3 ,2-d]pyrimidin-6-ylmethyl)- piperidin-4-yl]-(3-methanesulfonyl-propyl)-methyl-amine, prepared from (3- methanesulfonyl-propyl)-methyl-piperidin-4-yl-amine. Amine preparation: Toluene-4-sulfonic acid 3-methylsulfanyl-propyl ester was prepared from 3-(methylthio)-l-propanol using standard conditions. Treatment with mCPBA in DCM yielded <strong>[263400-88-0]toluene-4-sulfonic acid 3-methanesulfonyl-propyl ester</strong>. A mixture of 4-methylamino-piperidine- 1-carboxylic acid tert-butyl ester and <strong>[263400-88-0]toluene-4-sulfonic acid 3-methanesulfonyl-propyl ester</strong> was heated in MeCN in the prescence of potassium carbonate to yield 4- [(3-methanesulfonyl-propyl) -methyl- EPO <DP n="82"/>amino]-piperidine-l-carboxylic acid tert-butyl ester. Treatment of this compound with HCl in DCM/MeOH yielded the desired amine, isolated as the hydrochloride salt.1H NMR (400MHz, CDCl3) 1.50-1.70 (m, 4H, 2 x CH2), 1.90-1.97 (m, 2H, CH2), 2.00-2.05 (m, 2H, CH2), 2.21 (s, 3H, CH3), 2.38 (m, H, CH), 2.55 (m, 2H, CH2), 2.74 (s, 3H, CH2), 2.96-3.04 (m, 4H, 2 x CH2), 3.75 (s, 2H, CH2), 3.83-3.89 (m, 4H, 2 x CH2), 4.00-4.02 (m, 4H, 2 x CH2), 7.28 (s, H, CH), 7.41 (t, H, ArH, J=7.74Hz), 7.50 (d, H, ArH, J=8.24Hz), 8.18 (d, H, ArH, J=7.05Hz), 8.93 (s, H, ArH); MS (ESI+) 584.39 (MH+).
  • 2
  • [ 475-11-6 ]
  • [ 147539-41-1 ]
  • tert-butyl 4-[methyl(1-methyl-L-prolyl)amino]piperidine-1-carboxylate [ No CAS ]
YieldReaction ConditionsOperation in experiment
With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; Reference Example 5 By allowing benzyl 4-(methylamino)piperidine-1-carboxylate to react with EDCI hydrochloride, HOBt and 1-methyl-L-proline, tert-butyl 4-[methyl(1-methyl-L-prolyl)amino]piperidine-1-carboxylate was obtained. Then, trifluoroacetic acid was added thereto to obtain N,1-dimethyl-N-piperidin-4-yl-L-prolinamide. ES: 226.
  • 3
  • [ 22280-60-0 ]
  • [ 147539-41-1 ]
  • [ 1392430-01-1 ]
YieldReaction ConditionsOperation in experiment
With N-ethyl-N,N-diisopropylamine; In acetonitrile; at 65℃; for 30h; Step 1HCJNIG base (28.03 g, 0.217 mol) is added to the solution of 6-chloro-3-nitro-2- methylpyridine SM-3 (25 g, 145 mmol) and 4-methylamino-piperdine-1-carboxylic acid- te/f-butylester SM-5a (40.36 g, 188 mmol) in dry AcCN (200 mL) and stirred for 30 h at 65 °C. After the reaction is finished the reaction mixture is diluted with AcCN and water and stirred for 15 min. The precipitated product is collected by filtration, washed with water and the solid is dried in vacuo.
With N-ethyl-N,N-diisopropylamine; In acetonitrile; at 65℃; for 30h; HUeNIG base (28.03 g, 0.217 mol) is added to the solution of <strong>[22280-60-0]6-chloro-3-nitro-2-methylpyridine</strong> SM-3 (25 g, 145 mmol) and 4-methylamino-piperidine-1-carboxylic acid-tert-butylester SM-5a (40.36 g, 188 mmol) in dry AcCN (200 mL) and stirred for 30 h at 65° C. After the reaction is finished the reaction mixture is diluted with AcCN and water and stirred for 15 min. The precipitated product is collected by filtration, washed with water and the solid is dried in vacuo.
  • 4
  • [ 90176-80-0 ]
  • [ 147539-41-1 ]
  • tert-butyl 4-[[4-fluoro-2-(trifluoromethyl)phenyl]methyl(methyl)amino]piperidine-1-carboxylate [ No CAS ]
YieldReaction ConditionsOperation in experiment
79% 1-Boc-4-(methylamino)piperidine (800mg, 3.7mmol), and <strong>[90176-80-0]4-fluoro-2-(trifluoromethyl)benzaldehyde</strong> (0.56mL, 4.lmmol) were dissolved in DCM (l2mL) (plus molecular sieves) and stirred for 2 hours at room temperature. To the clear solution was added sodium triacetoxyborohydride (1 .1 8g, 5.6mmol) and the reaction was stirred over the weekend at room temperature. The reaction was diluted withDCM and then quenched with saturated NaHCO3 solution (aq). The organic and aqueous layers were separated and the aqueous layer further extracted with DCM. The organic layers were combined and concentrated in vacuo to give 1 .6g of crude product as a yellow oil. Purification by silica flash chromatography using 0% EtOAc in heptane with a gradient increasing to 50% ethyl acetate afforded tert-butyl 4-[[4-fluoro-2-(trifluoromethyl)phenyl]methyl-methyl-amino]piperidine-1 -carboxylate (1 .1 5g, 2.9mmol, 79%) as a pale yellow/clear oil.
  • 5
  • [ 14190-59-1 ]
  • [ 147539-41-1 ]
  • C15H23N3O3S [ No CAS ]
YieldReaction ConditionsOperation in experiment
With 1-hydroxy-7-aza-benzotriazole; N-ethyl-N,N-diisopropylamine; N-[(dimethylamino)-3-oxo-1H-1,2,3-triazolo[4,5-b]pyridin-1-yl-methylene]-N-methylmethanaminium hexafluorophosphate; In dichloromethane; at 20℃; for 12h; Step 1: To a solution of compound 1c (1 equivalent) in dichloromethane, compound 13a (1.5 eq.) was added sequentially.HOAT (1.5 eq.), HATU (2 eq.), DIPEA (6 eq.), stirred at room temperature for 12 hours.The solvent is then sparged off and directly isolated by column chromatography to afford intermediate 13b.
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 147539-41-1 ]

Amides

Chemical Structure| 301225-58-1

A172639 [301225-58-1]

tert-Butyl 4-(propylamino)piperidine-1-carboxylate

Similarity: 1.00

Chemical Structure| 108612-54-0

A191686 [108612-54-0]

tert-Butyl methyl(piperidin-4-yl)carbamate

Similarity: 1.00

Chemical Structure| 534595-51-2

A915900 [534595-51-2]

1-Boc-4-(isopropylamino)piperidine

Similarity: 1.00

Chemical Structure| 207405-68-3

A114194 [207405-68-3]

tert-Butyl endo-3-amino-8-azabicyclo[3.2.1]octane-8-carboxylate

Similarity: 0.98

Chemical Structure| 744183-20-8

A123720 [744183-20-8]

tert-Butyl exo-3-amino-8-azabicyclo[3.2.1]octane-8-carboxylate

Similarity: 0.98

Amines

Chemical Structure| 301225-58-1

A172639 [301225-58-1]

tert-Butyl 4-(propylamino)piperidine-1-carboxylate

Similarity: 1.00

Chemical Structure| 108612-54-0

A191686 [108612-54-0]

tert-Butyl methyl(piperidin-4-yl)carbamate

Similarity: 1.00

Chemical Structure| 534595-51-2

A915900 [534595-51-2]

1-Boc-4-(isopropylamino)piperidine

Similarity: 1.00

Chemical Structure| 207405-68-3

A114194 [207405-68-3]

tert-Butyl endo-3-amino-8-azabicyclo[3.2.1]octane-8-carboxylate

Similarity: 0.98

Chemical Structure| 744183-20-8

A123720 [744183-20-8]

tert-Butyl exo-3-amino-8-azabicyclo[3.2.1]octane-8-carboxylate

Similarity: 0.98

Related Parent Nucleus of
[ 147539-41-1 ]

Piperidines

Chemical Structure| 301225-58-1

A172639 [301225-58-1]

tert-Butyl 4-(propylamino)piperidine-1-carboxylate

Similarity: 1.00

Chemical Structure| 108612-54-0

A191686 [108612-54-0]

tert-Butyl methyl(piperidin-4-yl)carbamate

Similarity: 1.00

Chemical Structure| 534595-51-2

A915900 [534595-51-2]

1-Boc-4-(isopropylamino)piperidine

Similarity: 1.00

Chemical Structure| 87120-72-7

A143361 [87120-72-7]

tert-Butyl 4-aminopiperidine-1-carboxylate

Similarity: 0.98

Chemical Structure| 189819-75-8

A105977 [189819-75-8]

tert-Butyl 4-aminopiperidine-1-carboxylate hydrochloride

Similarity: 0.96